Hengyu Medical Secures Nearly CNY 1 Billion in New Funding to Advance Intravascular Imaging and Therapeutic Solutions

Recently, Horimed Technology Co., Ltd. (referred to as "Horimed") announced the completion of nearly 100 million yuan in financing. This round of financing was jointly invested by Guanghua Wutong, Chengdu Science and Technology Investment, and Zhongtian Weiyi. Xingqiao Capital served as the exclusive financial advisor. This is another significant financing completed by Horimed in 2025, which will help the company further accelerate the research and development, production, and commercialization process of vascular interventional endoluminal imaging and related therapeutic products.

The appeal of Horimed lies in its years of practical experience in the vascular intervention field, but more importantly, in its dedication to building a complete technical system and its irreplicable R&D capabilities. Having deeply engaged in the intravascular ultrasound (IVUS) and optical coherence tomography (OCT) technology fields for many years, Horimed has established a full-chain layout ranging from core components to complete equipment, and from single products to integrated system solutions. Horimed is one of the few companies in China that simultaneously masters both IVUS and OCT core technologies. This "dual-technology approach" has enabled Horimed to occupy a unique position in the field of precision vascular intervention diagnosis and treatment. Additionally, the successful integration of OCT with near-infrared spectroscopy (NIRS) into a single-source dual-modality OCT-NIRS technology has allowed Horimed to establish a tri-modality imaging model encompassing OCT/IVUS/NIRS, providing more comprehensive solutions for clinical diagnosis and treatment.